Maravai Lifesciences Holdings (MRVI) EBITDA (2020 - 2026)

Maravai Lifesciences Holdings' EBITDA history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• On a quarterly basis, EBITDA rose 95.61% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$168.3 million, a 36.72% increase from a year earlier, with the FY2025 full-year figure at -$215.3 million, up 8.64% from the prior year.
• EBITDA improved to -$2.2 million in Q1 2026 per MRVI's latest filing, from -$58.8 million in the prior quarter.
• Across five years, EBITDA topped out at $180.7 million in Q2 2022 and bottomed at -$165.6 million in Q3 2024.
• The 5-year median for EBITDA is -$13.4 million (2024), against an average of $5.3 million.
• Across the five-year window, EBITDA tumbled 974.23% in 2024 and surged 95.61% in 2026, its largest moves.
• Year by year, EBITDA stood at $109.2 million in 2022, then tumbled by 106.54% to -$7.2 million in 2023, then slumped by 427.3% to -$37.7 million in 2024, then tumbled by 55.95% to -$58.8 million in 2025, then jumped by 96.33% to -$2.2 million in 2026.
• Per Business Quant, the three latest MRVI EBITDA figures stand at -$2.2 million (Q1 2026), -$58.8 million (Q4 2025), and -$41.0 million (Q3 2025).